Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BHV-1530 · AMB302

Antibody-drug conjugate · Cytotoxic, directed at FGFR3 · developed by Biohaven

Phase 1 Most advanced trial

BHVN Developer

1 Registered trials

What is BHV-1530?

BHV-1530 is an antibody-drug conjugate comprising an anti-FGFR3 monoclonal antibody linked to a topoisomerase 1 inhibitor. The antibody targets FGFR3 on tumor cells; upon binding, the payload is released to inhibit topoisomerase 1 and kill FGFR3-expressing cells. It is studied in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AMB302
Drug type: Antibody-drug conjugate
Targets: FGFR3, DNA topoisomerase 1 (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at FGFR3
Pathways: DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: Biohaven (BHVN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06874335	Phase 1	Solid Tumor	Recruiting	BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

Other drugs acting on FGFR3

Nintedanib FDA approved CGT4859 Phase 1/2 Vepugratinib Phase 2

More from Biohaven

BHV-1300 Phase 3 BHV-1400 Phase 3 BHV-2100 Phase 2 BHV-700 Phase 1 BHV-7000 Phase 2/3 BHV-8000 Phase 2/3 PBI-410 Phase 1/2 Talditercept Alfa Phase 3 Troriluzole Phase 3 Verdiperstat Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHVN page.

Follow BHVN, the company behind BHV-1530

See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHVN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z